BB Biotech’s Achillion Pharmaceuticals ACHN Stock Holding History

BB Biotech’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,279,340	Closed	-$4.71M	–	35
2018 Q3	$4.71M	Hold	1,279,340	–	–	0.12%	32
2018 Q2	$3.62M	Hold	1,279,340	–	–	0.1%	32
2018 Q1	$4.75M	Hold	1,279,340	–	–	0.13%	30
2017 Q4	$3.68M	Hold	1,279,340	–	–	0.1%	30
2017 Q3	$5.74M	Hold	1,279,340	–	–	0.16%	27
2017 Q2	$5.87M	Hold	1,279,340	–	–	0.18%	28
2017 Q1	$5.39M	Hold	1,279,340	–	–	0.18%	30
2016 Q4	$5.28M	Hold	1,279,340	–	–	0.2%	29
2016 Q3	$10.4M	Hold	1,279,340	–	–	0.36%	28
2016 Q2	$9.98M	Hold	1,279,340	–	–	0.39%	26
2016 Q1	$9.88M	Hold	1,279,340	–	–	0.39%	27
2015 Q4	$13.8M	Hold	1,279,340	–	–	0.39%	28
2015 Q3	$8.84M	Hold	1,279,340	–	–	0.28%	28
2015 Q2	$11.3M	Hold	1,279,340	–	–	0.31%	27
2015 Q1	$12.6M	Buy	1,279,340 +200,000	+19%	+$2.5M	0.38%	27
2014 Q4	$13.2M	Sell	1,079,340 -200,000	-16%	-$2.44M	0.43%	27
2014 Q3	$12.8M	Sell	1,279,340 -500,000	-28%	-$4.64M	0.52%	23
2014 Q2	$13.5M	Hold	1,779,340	–	–	0.64%	23
2014 Q1	$5.85M	Hold	1,779,340	–	–	0.3%	22
2013 Q4	$5.91M	Hold	1,779,340	–	–	0.32%	22
2013 Q3	$5.37M	Buy	1,779,340 +100,000	+6%	+$685K	0.29%	24
2013 Q2	$13.7M	Buy	+1,679,340	New	+$12.8M	0.99%	17

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BB Biotech's ACHN Position: Q4 2018 in Review

BB Biotech sold out of Achillion Pharmaceuticals (ACHN) in Q4 2018, closing a stake of 1,279,340 shares — an estimated $4.71M sold.

BB Biotech first reported a position in ACHN in Q2 2013 and held it in 22 quarters. The position peaked at $13.8M in Q4 2015. 121 funds tracked by Wall St. Rank hold ACHN as of Q4 2018.

BB Biotech reported no remaining Achillion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
BB Biotech sold 1,279,340 Achillion Pharmaceuticals shares in Q4 2018, an estimated $4.71M.
BB Biotech first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 22 quarters.
BB Biotech's Achillion Pharmaceuticals position peaked at $13.8M in Q4 2015.
121 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2018.

Based on BB Biotech's 13F filing for Q4 2018, filed 12 Feb 2019.